Related Experiment Video
Updated: Oct 28, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
The Pharmacogenomics of Cisplatin-Induced Ototoxicity
David Harman1, Chiao Xin Lim2, Ganessan Kichenadasse3,4
1School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, SA 5000, Australia.
Abstract:
Cisplatin is a first line treatment for a wide range of cancers; one commonly observed adverse drug reaction (ADR) of cisplatin is ototoxicity. Onset of ototoxicity from cisplatin is inconsistent and no single risk factor can reliably predict whether a patient will develop ototoxicity. A genetic factor has been explored for these reasons. This study reviews and summarizes the strongest evidence toward a genetic association. A search of the literature was conducted across three databases for studies exploring the genetic association with cisplatin ototoxicity. 15 unique genes were observed by at least two unique studies with single nucleotide polymorphisms (SNPs), which significantly affected the likelihood of cisplatin-induced ototoxicity. There are many SNPs across a variety of genes that can significantly affect the likelihood of cisplatin-induced ototoxicity. Comparing the findings of studies is difficult because of significant heterogeneity in patient characteristics, treatment plans, and the classification of ototoxicity. Despite this, variants in ACYP2 (rs1872328), SLC22A2 (rs316019), and TLR4 (rs10759932) emerged as the most reproducible findings in this review.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Principles of Pharmacogenetics: Types of Genetic Variants
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetics of Drug Metabolism: Overview
